Treosulfan
 |
| Systematic (IUPAC) name |
| (2S,3S)-2,3-Dihydroxybutane-1,4-diyl dimethanesulfonate |
| Clinical data |
| AHFS/Drugs.com |
International Drug Names |
| Pregnancy cat. |
? |
| Legal status |
? |
| Routes |
Oral, IV |
| Identifiers |
| CAS number |
299-75-2  N |
| ATC code |
L01AB02 |
| PubChem |
CID 9296 |
| UNII |
CO61ER3EPI  Y |
| Synonyms |
1,2,3,4-Butanetetrol, 1,4-dimethanesulfonate, Threitol 1,4-dimethanesulfonate, Threitol 1,4-bismethanesulfonate; L-Threitol 1,4-bis(methanesulfonate); Ovastat; Threosulphan; Treosulphan; Tresulfan |
| Chemical data |
| Formula |
C6H14O8S2 |
| Mol. mass |
278.30056 g·mol−1 |
 N (what is this?) (verify)
|
Treosulfan is a substance that is being studied in the treatment of cancer.[1] It belongs to the family of drugs called alkylating agents. Its has been used mainly as a substitute of busulfan in frail patients, as the side effects and toxicity are supposedly less severe.
References [edit]
External links [edit]
- Treosulfan entry in the public domain NCI Dictionary of Cancer Terms
This article incorporates public domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".
(what is this?) (verify)
This article incorporates public domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".
